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HIV-1 vaccine design aims to develop an immunogen that elicits broadly neutralizing antibodies 21 
against a desired epitope, while eliminating responses to off-target regions of HIV-1 Env. Here 22 
we report isolation and characterization of Ab1245, an off-target antibody against the Env 23 
gp120-gp41 interface, from V3-glycan patch immunogen-primed and boosted macaques. A 24 
3.7Å cryo-EM structure of an Ab1245-Env complex reveals one Ab1245 Fab binding 25 
asymmetrically to Env trimer at the gp120-gp41 interface using its long CDRH3 to mimic regions 26 
of gp41. The mimicry includes positioning of a CDRH3 methionine into the gp41 tryptophan 27 
clasp, resulting in displacement of the fusion peptide and fusion peptide-proximal region. 28 
Despite fusion peptide displacement, Ab1245 is non-neutralizing even at high concentrations, 29 
implying that only two fusion peptides per trimer are required for viral–host membrane fusion. 30 
These structural analyses facilitate immunogen design to prevent elicitation of Ab1245-like 31 




Recent efforts in vaccine design for the HIV-1 virus have focused on developing neutralizing 36 
adaptive immune responses to the HIV-1 Env glycoprotein via sequential immunization1-3. 37 
Studies of broadly neutralizing antibodies (bNAbs) isolated from HIV+ human donors have 38 
informed immunogen design efforts for various epitopes on the Env trimer, including the V3-39 
glycan patch4,5, the fusion peptide (FP)6,7, and the CD4-binding site8,9. In some cases, on-target 40 
antibody responses are accompanied by off-target responses in which antibodies are made 41 
against undesired epitopes on the Env trimer including the ‘bottom’ or ‘base’ epitope10 and/or a 42 
minimally-glycosylated region (glycan ‘hole’)11. These antibodies target immunodominant but 43 
non-neutralizing epitopes and therefore do not contribute meaningfully to a neutralizing antibody 44 
response.  45 
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We previously described the design and characterization of RC1, a BG505 SOSIP.66412-based 47 
engineered immunogen targeting the V3-glycan patch on the gp120 subunit of Env trimer4. We 48 
showed that RC1 and/or RC1-4fill (modified from RC1 to include additional potential N-linked 49 
glycosylation sites; PNGSs) that had been multimerized on virus-like particles (VLPs) elicited 50 
antibodies that recognized the V3-glycan patch in wild-type mice, rabbits, and non-human 51 
primates (NHPs)4. We subsequently boosted a subset of RC1-4fill-primed NHPs, isolated single 52 
Env-specific B cells, and derived antibody sequences from which monoclonal antibodies (mAbs) 53 
were produced13.  Here, we describe a single-particle cryo-EM structure of a BG505 Env trimer 54 
bound to a monoclonal antibody (Ab1245) isolated from a rhesus macaque after a sequential 55 
immunization protocol that included multimerized HIV-1 SOSIP Envs derived from different 56 
clades. Ab1245 binds to an epitope overlapping with the FP-targeting bNAb VRC346 at the 57 
interface of the Env gp41 and gp120 subunits, but unlike VRC34, Ab1245 displaces the FP and 58 
fusion peptide-proximal region (FPPR). In addition, Ab1245 contains a methionine residue that 59 
structurally mimics Met530gp41, a key residue for the stability of the Env trimer, by engaging the 60 
“tryptophan clasp” formed by three gp41 tryptophan residues14,15. Despite inducing FP 61 
rearrangement and overlap with the neutralizing VRC34 epitope, Ab1245 did not neutralize 62 
BG505 or other viral strains, perhaps because of its sub-stoichiometric binding to Env trimer. 63 
These previously-unseen features of gp120-gp41 interface antibodies demonstrate that HIV-1 64 
Env can elicit non-neutralizing antibodies that block a neutralizing epitope, inform immunogen 65 
design protocols to prevent elicitation of similar antibodies, and provide potential mechanistic 66 
insight into HIV-1 Env-mediated fusion of the host and viral membranes. 67 
 68 
Results and Discussion 69 
 70 
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 4 
Sequential immunization after RC1-4-fill priming elicited Ab1245, a non-V3-targeting 71 
antibody 72 
We previously described a V3-glycan patch targeting immunogen, RC1, which was modified 73 
from a designed V3 immunogen, 11MUTB16, by removing the N-linked glycan attached to gp120 74 
residue N156gp1204. Both RC1 and 11MUTB were derived from clade A BG505 SOSIP.664 75 
native-like Env trimers12. RC1-4fill and 11MUTB-4fill were modified from RC1 and 11MUTB, 76 
respectively, to reduce antibody responses to off-target epitopes11,17-19 by inserting PNGSs to 77 
add glycans to residues 230gp120, 241 gp120, 289gp120, and 344gp1204. In addition, to enhance avidity 78 
effects and limit antibody access to the Env trimer base, we multimerized immunogens on VLPs 79 
using the SpyTag-SpyCatcher system20,21. Four NHPs primed with RC1-4fill-VLPs4 were 80 
boosted sequentially with (i) VLPS coupled with 11MUTB-4fill16 (clade A), (ii) VLPs coupled with 81 
B41 SOSIP (clade B), and (iii) VLPs coupled with a mixture of AMC011 and DU422 SOSIPs 82 
(clades B and C) over the course of 9 months. The sequences of the heavy and light chains of 83 
Ab1245 were generated by single cell cloning from B cells isolated from one of the boosted 84 
NHPs that were captured using BG505 and B41 SOSIPs as baits as described13 (Fig. 1a) The 85 
heavy and light chains were derived from the macaque V gene segments IGHV4-2*01 and 86 
IGLV9-1*01, respectively, and exhibited 14% (heavy chain) and 5% (light chain) amino acid 87 
changes due to somatic hypermutation. Of note, the third complementarity region (CDR) of the 88 
heavy chain (CDRH3) was longer than typical macaque CDRH3s (24 residues compared with 89 
an average of 13-15 residues22). Initial binding characterizations of the Ab1245 Fab showed that 90 
it bound to BG505 SOSIP and to both RC1 and RC1 glycan KO-GAIA (RC1 lacking the 91 
N301gp120 and N332gp120 glycans surrounding the V3-glycan patch with additional mutations to 92 
remove the gp120 GDIR sequence4), suggesting that it does not target the V3-glycan patch 93 
(Fig. 1b).  94 
 95 
Only one Ab1245 Fab binds to each BG505 SOSIP trimer 96 
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 5 
To determine the binding stoichiometry for the Ab1245 Fab interaction with BG505, we derived 97 
the absolute molecular mass of BG505-1245 Fab complexes using size-exclusion 98 
chromatography combined with multi-angle light scattering (SEC-MALS). When BG505 was 99 
incubated overnight with a 3-fold molar excess of Ab1245 Fab (three Fabs per gp120-gp41 100 
protomer), we observed a heterogeneous mixture corresponding to zero to one Ab1245 Fabs 101 
bound per trimer, whereas incubation with 8ANC195 Fab resulted in a homogeneous complex 102 
corresponding to three Fabs per trimer (Fig. 1c), as expected from previous stoichiometry 103 
measurements and structures23-25. To verify that one or more Ab1245 Fabs per trimer did not 104 
dissociate during the chromatography procedure required for SEC-MALS, we used mass 105 
photometry, a technique that derives approximate masses for individual proteins and complexes 106 
in solution26, to measure the molecular masses of BG505 alone and complexed with Ab1245 or 107 
with control Fabs: 8ANC195 (three Fabs per BG505 trimer)23-25 and BG1 (two Fabs per BG505 108 
trimer)23. Consistent with the SEC-MALS results, mass photometry experiments suggested zero 109 
to one Ab1245 Fabs bound to each wild-type BG505 trimer and to a N611A mutant BG505 110 
trimer (Fig. 1d). We conclude that Ab1245 Fab binds asymmetrically to Env with at most one 111 
Fab per trimer. 112 
 113 
Ab1245 binds at the gp120-gp41 interface 114 
To further characterize the Ab1245 epitope on HIV-1 Env, we solved a single-particle cryo-EM 115 
structure of Ab1245 Fab bound to a BG505 Env trimer. To form complexes, we incubated a 3-116 
fold molar excess of Ab1245 Fab with BG505, followed by an incubation with a 3-fold excess of 117 
8ANC19527 Fab to add mass to the complex and prevent problems associated with preferred 118 
orientation bias (Table 1, Supplementary Fig. 1c). This resulted in complex formation with three 119 
8ANC195 Fabs and a maximum of one Ab1245 Fab bound per BG505 trimer (Fig. 2a), 120 
consistent with the stoichiometry experiments (Fig. 1c,d). The complex with one Ab1245 Fab 121 
per BG505 trimer was solved at 3.7 Å resolution and showed generally well-defined side chain 122 
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density throughout the complex (Fig. 2b; Supplementary Fig. 1f). An additional 3D class of 123 
BG505 trimers was observed with three bound 8ANC195 Fabs and no Ab1245 Fabs 124 
(Supplementary Fig. 1e). 125 
 126 
The Ab1245-BG505-8ANC195 complex structure revealed non-overlapping epitopes at the 127 
gp120-gp41 interface for Ab1245 and 8ANC195 (Fig. 2a,b). The Ab1245 Fab was located at the 128 
interface between the gp120 and gp41 of its primary Env protomer and the gp41 of a 129 
neighboring protomer (Fig. 2c, Fig. 3a). By contrast, 8ANC195 recognized the gp120-gp41 130 
interface of a single protomer with no contacts to neighboring protomers (Fig. 2a), and 131 
equivalent interactions with the three BG505 protomers25. The Ab1245 epitope overlaps with 132 
that of VRC34, a FP-directed bNAb that binds with a three Fab per Env trimer stoichiometry at a 133 
site that is located closer to the trimer base6 than the Ab1245 epitope (Fig. 2d; Supplementary 134 
Fig. 2a). The Ab1245 heavy chain made the majority of contacts with BG505 (only three light 135 
chain residues contact BG505), and all but one of the 19 heavy and light chain contact residues 136 
were located within CDRs rather than antibody framework regions (FWRs) (Fig. 1a, Fig. 3b). 137 
The Ab1245 CDRH1 and CDRH2 loops formed extensive interactions with a portion of gp120 138 
between residues Pro79gp120 and Glu87gp120 (Fig. 3c), while the long (24-amino acid) CDRH3 139 
loop contacted gp41 residues as well as residues at the termini of gp120 that fit inside the 140 
previously-defined membrane-proximal collar14 (Fig. 3d). The Ab1245 light chain made contacts 141 
with the terminal helix of an adjacent gp41 subunit, which had undergone a change in 142 
conformation from a helix to a unstructured region that was partially disordered, suggesting the 143 
possibility that the gp41 helix conformation sterically interferes with binding, as was also 144 
proposed for the interaction of the human bNAb 3BC315 with BG505 Env trimer28 (Fig. 3a,e). 145 
The majority of the Ab1245 Fab contacts with BG505 were contacts to protein residues, with the 146 
only glycan contact involving the third framework region of the antibody heavy chain (FRWH3) 147 
with a terminal sugar on the Asn448gp120 glycan (Fig. 3a). By contrast, the 8ANC195 epitope 148 
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 7 
includes required contacts with glycans attached to residues Asn276gp120 and Asn234gp12025,29, 149 
and the VRC34 epitope includes contacts with glycans at residues Asn88 gp120 and Asn241 gp1206 150 
(Fig. 2d). The possibility that an N-glycan attached to Asn611gp41 could occlude Ab1245 Fab 151 
binding was suggested by a lack of density for this glycan on the primary Ab1245-binding 152 
protomer compared with density for one GlcNAc attached to the Asn611gp41 residues on the 153 
other two protomers (Supplementary Fig. 2b). However, only one Ab1245 Fab bound to a 154 
soluble BG505N611A trimer (Fig. 1d), implying that the presence of the Asn611gp41 glycan does 155 
not account for sub-stoichiometric binding of Ab1245 to Env trimers. 156 
 157 
The Ab1245 CDRH3 contains a gp41 mimicry motif 158 
Unlike binding of the FP-specific bNAb VRC346 or any other reported HIV-1 antibody, Ab1245 159 
binding to BG505 Env trimer resulted in displacement of the FP (residues 512gp41-527gp41) and 160 
FPPR (residues 528gp41-540gp41) of the gp41 subunit within the primary protomer to which 161 
Ab1245 was bound (Fig. 4a,b). The FP/FPPR displacement resulted from intercalation of the 162 
Ab1245 CDRH3 (Fig. 4a). Although the gp41 residues of HR1N (547gp41-568gp41) are usually 163 
disordered in structures of Env trimer (except when an interface antibody is bound), residues N-164 
terminal to this region, 520gp41-546gp41, are ordered whether or not the Env was complexed with 165 
a gp120-gp41 interface antibody (e.g.,30,31). In the Ab1245-BG505 complex structure, there was 166 
no observed density for residues spanning 512gp41-565gp41 on the primary gp41 to which Ab1245 167 
was bound, thus both regions of gp41 were disordered. The disorder resulted from Ab1245 168 
binding because residues 520gp41 to 546gp41 were resolved in the two adjacent gp41 subunits 169 
(Fig. 4b).  170 
 171 
One of the disordered gp41 residues in the Ab1245-BG505-8ANC195 structure, Met530gp41, 172 
normally inserts into the gp41 ‘tryptophan clasp’ formed by residues Trp623gp41, Trp628gp41, and 173 
Trp631gp4114,15 (Fig. 4a). The tryptophan clasp has been hypothesized to be a key interaction 174 
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 8 
that stabilizes the Env trimer in both its closed, prefusion conformation and its CD4-bound open 175 
conformation, and it has been speculated that the disengagement of Met530gp41 from the 176 
tryptophan clasp triggers elongation of HR1 into a full-length helix and the large rearrangement 177 
of the FP required for insertion into the host membrane14,15.  However, the primary protomer to 178 
which Ab1245 is bound contained a disengaged Met530gp41, but adopted most structural 179 
characteristics of a closed, prefusion Env trimer (Fig. 2a,b). The limited structural changes in 180 
Ab1245-bound BG505 from other closed Env trimer structures included disorder of the gp41 FP 181 
and FPPR regions, a transition to an unstructured secondary structure in a gp41 terminal helix, 182 
a shift in the N88gp120 glycan, and absence of density for the N611gp41 glycan (Fig. 4a; 183 
Supplementary Fig. 2c). The stability of the Ab1245-bound BG505 trimer in the closed 184 
conformation despite displacement of Met530gp41 from the tryptophan clasp is rationalized by 185 
the insertion of an Ab1245 CDRH3 residue, Met100c1245 HC, into the gp41 tryptophan clasp to 186 
mimic Env residue Met530gp41 (Fig. 4a,c). 187 
 188 
Some HIV-1 gp120-gp41 interface-binding antibodies induce dissociation of Env trimers into 189 
protomers after incubation for 30 minutes to several hours28,32. Disruption of residue(s) within 190 
the gp41 tryptophan clasp was hypothesized to be the mechanism by which these antibodies 191 
induce trimer dissociation28,33,34. Indeed, Met530gp41, which is part of the disordered gp41 region 192 
that is displaced by Ab1245 binding, has been implicated as an important anchoring residue that 193 
mediates gp41 dynamics35. However, we found no dissociation of Env trimers into protomers in 194 
the cryo-EM structure of the Ab1245-BG505-8ANC195 complex that was derived after an 195 
overnight incubation of BG505 with Fabs or indication of dissociated protomers by SEC-MALS 196 
(Fig. 1c). We hypothesize that disruption of the tryptophan clasp by Ab1245 does not induce 197 
trimer dissociation because insertion of its CDRH3 residue Met100c1245 HC mimics gp41 198 
Met530gp41 to stabilize the tryptophan clasp conformation (Fig. 4a,b).  199 
 200 
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 9 
Ab1245 IgG is non-neutralizing 201 
Although Ab1245 Fab exhibits strong binding to BG505 SOSIP Env (Fig. 1b), we observed no 202 
neutralization of a BG505 pseudovirus at Ab1245 IgG concentrations up to 1 mg/mL (Fig. 1e). 203 
Additionally, we observed no neutralization by Ab1245 Fab at concentrations up to 100 μg/mL 204 
for eight strains of pseudovirus (unpublished data).  205 
 206 
A recent report described RM20E1, an antibody isolated from BG505-immunized NHPs, which 207 
neutralized an N611Agp41 mutant strain of BG505, but not the wild-type version of BG50536. In 208 
common with Ab1245, RM20E1 binds BG505 SOSIP sub-stoichiometrically at an epitope that 209 
overlaps with the Ab1245 epitope, but it does not displace the FP or FPPR. To determine 210 
whether the Asn611gp41 glycan interferes with Ab1245 neutralization of BG505 or viral strains 211 
containing a glycan at this position, we also evaluated neutralization of Ab1245 against a 212 
BG505N611A strain and eight other HIV-1 strains that lack a PNGS at position 611gp41. We 213 
observed no neutralization by Ab1245 IgG against any of the viral strains under conditions in 214 
which a positive control IgG exhibited neutralization (Fig. 1e).  215 
 216 
The fact that the Ab1245 was elicited by a SOSIP immunogen implies that non-neutralizing 217 
gp41-mimicking antibodies could be raised during other vaccination experiments. Important 218 
features of Ab1245 that allow its gp41 mimicry include a long CDRH3 with a methionine roughly 219 
in the middle (Met100c1245 HC is the 11th residue of the 24 amino acid CDRH3). A search of the 220 
Protein Data Bank37 for Fab structures with features of the Ab1245 CDRH3 (22-26 residue 221 
length and a methionine at position 7-13) revealed three of 1657 Fabs with these features 222 
(PDBs 5CEZ, 6E4X, and 2XTJ). However, the conformations of the CDRH3s of these Fabs did 223 
not resemble the Ab1245 CDRH3 conformation (data not shown). Given that the features 224 
required for Ab1245 mimicry of gp41 are apparently rare (i.e., not found in a survey of other 225 
antibody structures), Ab1245 CDRH3 characteristics (~24 residue CDRH3 with a methionine at 226 
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 10 
position ~11) could be used to screen elicited antibody sequences to identify Ab1245-like 227 
antibodies that are likely to be non-neutralizing. In addition, the Ab1245-BG505 complex 228 
structure could inform the engineering of SOSIP immunogens to prevent displacement of the FP 229 
and FPPR residues surrounding Met530gp41.  230 
 231 
Our results suggest that Ab1245 binds to at least some strains of Env trimer (e.g., BG505) on 232 
virions, but does not affect entry into target cells. Since only one Ab1245 Fab binds per Env 233 
trimer at a site that would not disrupt CD4 binding, Env trimers should still be able to undergo 234 
CD4-induced conformational changes38-41 allowing coreceptor binding and subsequent insertion 235 
of one or two of the trimer FPs into the host cell membrane. This would imply that fusion 236 
requires only up to two of three FPs to be inserted into the target membrane. However, it is also 237 
possible that the third FP, which was displaced by Ab1245 binding and is disordered in the 238 
Ab1245-BG505 structure (Fig. 4a), could access the host cell membrane and insert itself 239 
despite Ab1245 binding, thus enabling all three FPs per Ab1245-bound Env trimer to function in 240 
membrane fusion.  241 
 242 
The characterization of Ab1245 reported here suggest that, in order for an antibody against the 243 
FP epitope to be neutralizing, it must directly bind the FP in order to prevent it from inserting into 244 
the host cell membrane. Thus displacement of the FP and FPPR by an antibody such as 245 
Ab1245 through gp41 mimicry need not result in neutralization. However, by blocking 246 
neutralizing antibodies such as VRC34, an antibody that directly interacts with the FP6, from 247 
binding HIV-1 Envs, Ab1245 and similar antibodies could serve as decoys that protect a 248 
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Single B cell sorting and antibody sequencing. 253 
Cells from lymph node biopsies obtained from immunized macaques were thawed and washed 254 
in RPMI medium 1640 (1x) (Gibco #11875-093). Macaque cells were incubated with 100 μl of 255 
FACS buffer (PBS 1x with 2% fetal bovine serum and 1mM EDTA) with human Fc Block (BD 256 
Biosciences #564219) at a 1:500 dilution for 30 min on ice.  257 
 258 
BG505 and B41 tetrameric baits were prepared by incubating 5 μg of AviTagged and 259 
biotinylated BG505 and B41 SOSIP trimers with fluorophore-conjugated streptavidin at a 1:200 260 
dilution in 1xPBS for 30 min on ice as previously reported4,42. Tetramers were mixed with the 261 
following anti-human antibody cocktail: anti-CD16 APC-eFluor780 (Invitrogen, #47-0168-41), 262 
anti-CD8a APC-eFluor780 (Invitrogen, #47-0086-42), anti-CD3 APC-eFluor780 (Invitrogen, #47-263 
0037-41), anti-CD14 APC-eFluor780 (eBiosciences, #47-0149-41), anti-CD20 PeCy7 (BD, 264 
#335793), anti-CD38 FITC (Stem Cell technologies, #60131FI) at a 1:200 dilution and the 265 
live/dead marker Zombie NIR at a 1:400 dilution in FACS buffer. 266 
 267 
Zombie NIR-/CD16-/CD8a-/CD3-/CD14-/CD20+/CD38+/double BG505+ and B41+ single 268 
cells were isolated from the macaque cell homogenates using a FACS Aria III (Becton 269 
Dickinson). Single cells were sorted into individual wells of a 96-well plate containing 5 μl of lysis 270 
buffer (TCL buffer (Qiagen #1031576) with 1% of 2-b-mercaptoethanol). Plates were 271 
immediately frozen on dry ice and stored at -80ºC. 272 
 273 
Antibody sequencing and cloning were performed as previously described4. Assignments of V, 274 
D, and J genes, percent mutated from germline sequences, and identification of CDR loops for 275 
Fig. 1a were done using IMGT/V-QUEST analysis using genes from the species macaca 276 
mulatta43-45. Percent change from germline does not include a one-amino acid insertion in the 277 
Ab1245 heavy chain. Residues were numbered according to the Kabat convention46.  278 
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Protein Expression 280 
Fabs (Ab1245, 8ANC195, BG1) and IgGs (Ab1245, N6) were expressed and purified as 281 
described47. Briefly, IgGs and 6xHis-tagged Fabs were expressed by transient transfection of 282 
paired heavy chain and light chain expression plasmids into HEK293-6E or Expi293 cells (Life 283 
Technologies). Fabs and IgGs were purified from transfected cell supernatants using Ni-NTA 284 
(GE Healthcare) (for Fabs) or protein A (GE Healthcare) (for IgG) affinity chromatography 285 
followed by SEC on a Superdex 200 16/60 column (GE Healthcare). Proteins were stored in 20 286 
mM Tris, pH 8.0, and 150 mM sodium chloride (TBS buffer). 287 
 288 
BG505 SOSIP.664, a soluble clade A gp140 trimer that includes ‘SOS’ substitutions 289 
(A501Cgp120, T605Cgp41), the ‘IP’ substitution (I559Pgp41), the N-linked glycan sequence at 290 
residue 332gp120 (T332Ngp120), an enhanced gp120-gp41 cleavage site (REKR to RRRRRR), and 291 
a stop codon after residue 664gp41 (Env numbering according to HX nomenclature)12 was 292 
expressed in a stable CHO cell line (kind gift of John Moore, Weill Cornell Medical College) as 293 
described48. BG505N611A SOSIP was expressed by transient transfection in Expi-293 cells as 294 
described25. SOSIP proteins were isolated from cell supernatants using a 2G12 immunoaffinity 295 
column made by covalently coupling 2G12 IgG monomer to an NHS-activated Sepharose 296 
column (GE Healthcare). Protein was eluted with 3M MgCl2 followed by buffer exchange into 297 
TBS, and trimers were purified using Superdex 200 16/60 SEC (GE Healthcare), and then 298 
stored in TBS. 299 
 300 
SEC-MALS 301 
Purified BG5505 SOSIP and BG505-Fab complexes were characterized by SEC-MALS to 302 
determine absolute molecular masses49. For complexes, BG505 SOSIP.664 was mixed with a 303 
3-fold molar excess of Ab1245 Fab or 8ANC195 Fab relative to BG505 trimer in TBS. 304 
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 13 
Complexes were incubated overnight at room temperature and injected onto a Superdex 200 305 
10/300 GL gel-filtration chromatography column equilibrated with TBS. The chromatography 306 
column was connected with an 18-angle light-scattering detector (DAWN HELEOS II; Wyatt 307 
Technology), a dynamic light-scattering detector (DynaPro Nanostar; Wyatt Technology), and a 308 
refractive index detector (Optilab t-rEX; Wyatt Technology). Data were collected every second 309 
at 25°C at a flow rate of 0.5 mL/min. Calculated molecular masses were obtained by data 310 
analysis using the program ASTRA 6 (Wyatt Techonology). 311 
 312 
Mass photometry  313 
Microscope coverslips (No. 1.5, 24 × 50 mm, VWR) were cleaned by sequential rinsing with 314 
Milli-Q H2O followed by isopropanol and again Milli-Q H2O followed by drying using a filtered 315 
pressured air stream. Clean coverslips were assembled using CultureWell™ reusable silicon 316 
gaskets (Grace Bio-Labs, # 103250). Measurements were performed using a OneMP mass 317 
photometer (Refeyn Ltd, Oxford, UK). Immediately before each measurement, wells were filled 318 
with 15 µl TBS buffer. The focal position was identified and secured in place with an autofocus 319 
system based on total internal reflection for the entire measurement. Immediately following the 320 
focusing procedure, 1 µl of protein solution was added and gently mixed by pipetting up and 321 
down 3 times at a 5 µl mixing volume. Calibration standards (1 µM Bovine Serum Albumin 322 
(BSA) SIGMA #23209 and 500 nM apoferritin SIGMA #A3360) were measured first. SOSIP-Fab 323 
complexes (incubated at 7 µM SOSIP and ~7.7 µM Fab for either 2-5 days or for 1-2 hours and 324 
subsequently diluted 1:6 in TBS) was added to the 15 µl PBS buffer in the well resulting in an 325 
~114 nM concentration with respect to the SOSIP unless indicated otherwise. Recording of a 326 
mass photometry movie was started immediately. Data acquisition was performed using 327 
AcquireMP 2.2.0 software (Refeyn Ltd.), and data analysis was carried out using DiscoverMP 328 
2.2.0 software (Refeyn Ltd.). Resulting mass photometry graphs were evaluated and protein 329 
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complex masses were determined against the BSA/apoferritin calibration measurements carried 330 
out on the same day. 331 
 332 
Complex formation and cryo-EM data collection 333 
Ab1245-BG505 complex was prepared by adding a 3-fold molar excess of Ab1245 Fab (Fab to 334 
BG505 protomer) to CHO-expressed BG505 SOSIP.664 isolated from the second half of a 335 
monodisperse SEC peak. This mixture was incubated at room temperature for three hours, after 336 
which a 3-fold molar excess of 8ANC195 Fab to BG505 protomer was added and the complex 337 
was incubated at room temperature overnight. The Ab1245-BG505-8ANC195 complex was then 338 
purified using size-exclusion chromatography (Superdex 200) and concentrated to 4.7 mg/mL 339 
before vitrification on a freshly-glow discharged (15 mA for 1 min, Ted Pella PELCO easiGLOW) 340 
Quantifoil R 2/2 300 mesh Cu grid (Electron Microscopy Services). Samples were vitrified using 341 
a Mark IV Vitrobot (Thermo Fisher) in 100% liquid ethane after a 3 second blot with Whatman 342 
No. 1 filter paper at 22°C and 100% humidity. Micrograph movies were collected on a Titan 343 
Krios using SerialEM50 automated collection software with a K3 camera (Gatan) operating in 344 
super resolution mode at a nominal magnification of 105,000x (0.433 Å/ pixel) using a defocus 345 
range of -0.8 to -2.5 µm. The dose was 1.5 e-/Å2 over 40 frames, resulting in a total dose of 60 346 
e-/Å2. Data collection conditions are summarized in Supplementary Table 1.  347 
 348 
Cryo-EM data processing 349 
Processing was carried out entirely within Relion-351,52. First, micrograph movies were motion 350 
corrected, dose-weighted, and binned to 0.866 Å/pixel using Motioncor253, and then the non-351 
dose-weighted micrographs were used for CTF estimation using Gctf54. Micrographs with poor 352 
CTF fits or signs of crystalline ice were discarded. Selected micrographs then underwent auto-353 
picking after which 4x4 binned particles were extracted (3.46 Å/pixel). These particles were then 354 
subjected to reference-free 2D classification after which selected particles underwent three 355 
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rounds of iterative 3D classification, wherein classes representing 8ANC195–BG505 were 356 
discarded and only the final particles representing 1245–BG505–8ANC195 were selected and 357 
unbinned (0.866 Å/pixel). Finally, these unbinned particles underwent 3D refinement (C1 358 
symmetry imposed) and were post-processed into a map with a gold-standard FSC calculation55 359 
of 3.7 Å. A ‘blurred’ map was also created using a higher B-factor to uncover N-linked glycan 360 
densities. 361 
 362 
Model building 363 
Coordinates of BG505-8ANC195 Fab VH-VL domains (PDB 5CJX) and VRC34 Fab VH-VL 364 
domains (PDB 6NC3) were fitted into map density using UCSF Chimera56. Coordinates were 365 
then built into densities using iterative rounds of refinement in Phenix57 (rigid body and real-366 
space refinement) and Coot58. Antibody numbering was done in the Kabat convention using the 367 
online ANARCI server59. 368 
 369 
Structural analysis 370 
Structure figures were made using UCSF Chimera56 or PyMol60. Contact residues were 371 
assigned as residues with any atom located <4.0 Å from an atom in a residue on the partner 372 
molecule. Hydrogen bond interactions were not assigned due to limited resolution. 373 
 374 
In vitro neutralization assays   375 
Pseudovirus neutralization assays were conducted as described61 either in-house (for strains 376 
BG505, BG505N611A, CE0217, CNE55, JRCSF, Du422, T250-4, Tro, X1632, 246F3, CH119, 377 
CE1176, BJOX002000_03_02, 25710, X2278, CNE8, and 398F1) or by the Collaboration for 378 
AIDS Vaccine Discovery (CAVD) core neutralization facility (for the remaining strains in Fig. 1e). 379 
IgGs (Ab1245 and an N662 positive control) were evaluated in duplicate with an 8-point, 4-fold 380 
dilution series starting at a top concentration of 500 or 1000 µg/mL for in-house neutralizations 381 
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or an 8-point, 5-fold dilution series starting at a top concentration of 250 µg/mL at the CAVD 382 
facility. 383 
Data Availability 384 
The atomic model and and cryo-EM maps have been deposited in the Protein Data Bank (PDB) 385 
accession code XXXX and Electrion Microscopy Data Bank (EMDB) entry EMD-XXXXX.  386 
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Figure 1. Characterization of Ab1245 elicited in macaques by sequential immunization.  a, 415 
Sequence alignment of Ab1245 heavy and light chains with their germline precursors. Contacts 416 
with BG505 Env are indicated by a colored box around the residue (cyan box of CDRH3 contact 417 
residues; dark pink and light pink boxes for heavy chain and light chain contact residues, 418 
respectively). Residues within CDRs are indicated; residues between CDRs are within 419 
framework regions (FWRs). CDRH3 residues derived from VDJ joining are shown as dashes in 420 
the top germline sequence, and changes from the germline precursors are denoted a different 421 
residue in the mature Ab1245 sequence. Residues are numbered using the Kabat convention. 422 
b, SPR comparing binding of Ab1245 Fab to RC1, BG505, and RC1 glycan KO-GAIA. c, SEC-423 
MALS profiles for BG505 SOSIP.664 Env trimer alone and complexed with a 3-fold molar 424 
excess of Ab1245 and 8ANC195 Fabs. Left: absorbance at 280 nm (left y-axis) plotted against 425 
elution volume from a Superdex 200 10/300 GL gel filtration column overlaid with the molar 426 
mass determined for each peak (right y-axis). Right: Table showing predicted and calculated 427 
molecular masses.  d, Mass photometry results. Derived molecular masses (MW) are listed for 428 
Env trimers (either BG505 or BG505N611A) incubated without an added Fab or with the indicated 429 
Fab (Ab1245, BG1, or 8ANC195) as mean and standard deviation for the indicated number of 430 
independent measurements. The Fabs/trimer row shows the expected number of Fabs for each 431 
Fab/Env trimer complex. The predicted mass row shows the mass calculated assuming 310 432 
kDa for BG505 trimer (derived by SEC-MALS, panel b) plus 50 kDa per bound Fab. e, In vitro 433 
neutralization assays using IgGs Ab1245 or N662 (positive control for neutralization) against the 434 
indicated viral strains. In addition to those listed, Ab1245 was tested in-house against 435 
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pseudoviruses from strains CE0217, CNE55, JRCSF, Du422, T250-4, Tro, X1632, 246F3, 436 
CH119, CE1176, BJOX002000_03_02, 25710, X2278, CNE8, and 398F1 at a top concentration 437 
of 500 µg/mL or 1000 µg/mL along with IgG N6 (positive control at a top concentration of 10 438 
µg/mL). Whereas N6 exhibited expected neutralization potencies62, Ab1245 exhibited no 439 
neutralization activity.  440 
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Figure 2. Ab1245 binds the gp120-gp41 interface. a, Representation of Ab1245-BG505-443 
8ANC195 structure. Fabs are shown in cartoon, BG505 is shown as surface, and glycans are 444 
shown as sticks. Within BG505, gp120 is light gray and gp41 is dark gray. The Ab1245 VH-VL is 445 
dark pink (heavy chain) and light pink (light chain); 8ANC195 Fabs are dark green (heavy chain) 446 
and light green (light chain). b, Side view (left) and view looking up from the trimer base (right) 447 
of density map for 3.7 Å Ab1245-BG505-8ANC195 complex. Colors as in panel a. c, Close-up 448 
view of Ab1245 VH-VL domains (cartoon) interacting with gp120-gp41 interface with highlighted 449 
CDRH3 (cyan). N-linked glycans are light gray (gp120), dark gray (gp41), or yellow (N88gp120 450 
and N241gp120 glycans) spheres. d, Cartoon representation of VRC34-AMC11 SOSIP structure 451 
(PDB 6NC3) from same view as c (left) and a different view from above the trimer (right). 452 
VRC34 heavy and light chains (PDB 6NC3) are dark and light purple, respectively. 453 
 454 
  455 
.CC-BY-NC 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 





Figure 3. Ab1245 CDRH3 makes the majority of contacts to BG505 Env. a, Surface 458 
representation of BG505 trimer with colored highlights showing the epitopes of Ab1245 (light 459 
and dark pink with CDRH3 contacts highlighted in cyan and pink sticks for glycan contacts) and 460 
8ANC195 (green, with green sticks representing glycans within the epitope). Glycans 461 
represented that are not part of an epitope are shown as gray sticks. b, Cartoon representation 462 
of Ab1245 with paratope residue atoms shown as colored spheres. c, gp120 interactions with 463 
Ab1245 CDRH1 and CDRH2 loops (dark pink spheres). gp120 is gray with contacts to Ab1245 464 
highlighted in orange. Sidechains of gp120 contacts are shown as sticks. The Ab1245 paratope 465 
is represented as in panel b. d, Interactions of Ab1245 CDRH3 (cyan spheres) with gp120 (light 466 
gray) and gp41 (dark gray). Contacting residues are orange, and side chains discussed in the 467 
text are shown. e, Ab1245 light chain (light pink spheres) contacts with the terminal helix of an 468 
adjacent gp41. Contacting residues are orange with side chains shown.  469 
 470 
  471 
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Figure 4. Ab1245 CDRH3 mimics gp41 interactions with the tryptophan clasp. a, Cartoon 474 
representation of the interactions between Ab1245 VH-VL domains (pink with CDRH3 in cyan) 475 
and the tryptophan clasp of gp41 (gp41 in dark gray with Trp residues 623gp41, 628gp41, and 476 
631gp41 in dark blue) with gp120 in light gray. Interacting residues between M100cHC and the 477 
tryptophan clasp shown as sticks. b, Cartoon representation of the same view of an unbound 478 
protomer of gp41 with the portion of gp41 containing the fusion peptide (red) and fusion peptide 479 
proximal region (FPPR, green) interacting with the gp41 tryptophan clasp (same coloring as in 480 
a). Interactions between M530gp41 and the tryptophan clasp are shown as sticks. c, Surface 481 
representation of gp41 (dark gray) and gp120 (light gray) with tryptophan clasp residues in dark 482 
blue. Ab1245 CDRH3 is cyan with a stick representation for the Met100cHC sidechain. 483 
 484 
 485 
Table 1. Data collection and refinement statistics 486 
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Dose rate (e-/pixel/s) 25
Electron dose (e-/Å2) 60
Defocus range (µm) 0.8 - 2.5
Pixel size (Å) 0.866
Micrographs collected 2,307
Micrographs used 2,260




FSC 0.5 (unmasked/masked) 4.0/3.7
FSC 0.143 (unmasked/masked) 3.6/3.5
Refinement and Validation
Initial model used 5CJX, 6NC3
Number of atoms 22,171
Protein (residues) 2,634
Ligands BMA:11; NAG:87; MAN:30
MapCC (global/local)
Map sharpening B-factor 171
R.m.s. deviations
Bond lengths (Å) 0.003
Bond angles (˚) 0.598
MolProbity score 1.42
Clashscore (all atom) 4.2
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Supplementary Fig. 1. Cryo-EM Data Processing. a, Representative motion-corrected 490 
micrograph. b, 4x-binned selected 2D classes. c, Orientation distribution analysis. d, Local 491 
resolution map from two angles. e, Map of 3D class that contained 3 8ANC195 Fabs and no 492 
Ab1245 Fabs (colors as in Fig. 2b). f, Representative images of map quality at indicated sites 493 
for the 3.7 Å Ab1245–BG505–8ANC195 cryo-EM structure. 494 
 495 
  496 
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Supplementary Fig. 2. Ab1245 Structural Analysis. a, Comparison of binding of gp120-gp41 499 
interface or fusion peptide-directed antibodies. Left: BG505 trimer (gray surface) and Fab VH-VL 500 
domains (colored surfaces). Insets: individual antibodies bound to Env trimer (gray) are shown 501 
as cartoon with the FP in red and the FPPR in orange. b, Comparison of density for the 502 
N611gp41 glycan on gp120 (gray cartoon), with 8ANC195 (green cartoon), and Ab1245 (pink 503 
cartoon with non-blurred (blue) and blurred (red) maps shown as mesh). c, Comparison of 504 
secondary structure between protomers of gp120-gp41 with Ab1245 bound (red cartoon) and 505 
not bound (shades of teal, cartoon). Glycans are shown as spheres, and differences between 506 
bound and unbound protomers are highlighted with arrows and descriptions.   507 
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